Sesen Bio, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

It is alleged in this complaint that Sesen failed to disclose to investors: (1) that Sesen Bio’s clinical trial in relation to Vicineum had more than 2,000 violations of trial protocol, which included 215 classified as “major”; (2) that three of Sesen Bio’s clinical investigators were convicted of “serious noncompliance,” which included “back-dating data”; (3) that Sesen Bio had submitted the tainted data in relation to the BLA for Vicineum; (4) that Sesen Bio’s clinical trials found that Vicineum leaked out into the body, which led to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) that, as a result of the foregoing, t was not likely Sesen’s BLA for Vicineum would be approved; (6) that, as a result of the foregoing, there was a reasonable likelihood that additional trials would be required to be conducted to support the efficacy and safety of Vicineum; and (7) that, as a result of the foregoing, Sesen’s positive statements in regard to Sesen’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.